The basics

What is Stage III lung cancer?

Stage III lung cancer means the tumor has grown beyond the lung and involved regional lymph nodes or adjacent structures, but has not spread to distant sites like the liver, bones, or brain. About 25–30% of NSCLC patients are diagnosed at Stage III. It is a heterogeneous group — some Stage IIIA patients can undergo surgery; most Stage IIIB and virtually all Stage IIIC patients cannot, and are treated with definitive chemoradiation instead.

The landmark trial that defines current Stage III NSCLC treatment is the PACIFIC trial, which showed that durvalumab (Imfinzi) maintenance after concurrent chemoradiation significantly improved progression-free and overall survival in unresectable Stage III NSCLC. This is now standard of care worldwide. Current clinical trials are building on this foundation — testing whether adding novel agents to the PACIFIC regimen, or replacing durvalumab with a more potent approach, can push further. Molecular testing (NGS) matters at Stage III too: EGFR-mutant patients, for example, have poor responses to durvalumab and different adjuvant options (osimertinib).

Stage III Substages — What They Mean for Trials

The substage determines resectability, which determines your entire treatment pathway and trial landscape:

Stage IIIA

Potentially resectable in selected patients

Involves ipsilateral mediastinal (N2) lymph nodes or T4 tumor with N1 nodes. Resectability is debated and highly center-dependent. Some patients receive neoadjuvant chemotherapy or chemo-immunotherapy before surgery. Trials specifically targeting resectable Stage IIIA with perioperative immunotherapy (nivolumab, pembrolizumab) are actively enrolling.

Stage IIIB

Generally unresectable

Involves contralateral mediastinal or supraclavicular lymph nodes (N3), or T4 tumor with N2 nodes. Surgery is rarely possible. Definitive concurrent chemoradiation followed by durvalumab maintenance (PACIFIC regimen) is standard. Most Stage III clinical trials enroll IIIB patients as their core population.

Stage IIIC

Definitively unresectable

T4 tumor with N3 nodes. Always treated non-surgically. Same chemoradiation + durvalumab approach as IIIB. Patients with IIIC may have larger radiation fields and more complex treatment planning, which can affect eligibility for trials requiring adequate lung function (FEV1, DLCO).

Limited-Stage SCLC

Roughly equivalent to Stage III

SCLC uses limited-stage (fits in one radiation field) vs. extensive-stage rather than the TNM I–IV system. Limited-stage SCLC roughly corresponds to Stage I–III NSCLC. If your diagnosis is SCLC, see the dedicated SCLC page — treatment logic is completely different from NSCLC Stage III.

Stage III Trial Pathways by Treatment Approach

Neoadjuvant (Pre-Surgery, Resectable IIIA)

If your multidisciplinary team has determined your Stage IIIA disease is potentially resectable: neoadjuvant chemo-immunotherapy trials are the most active area. Nivolumab + chemotherapy (CheckMate 816) is FDA-approved neoadjuvant for resectable NSCLC. Active trials are testing nivolumab, pembrolizumab, and durvalumab combinations before surgery, with pathological complete response (pCR) as the primary endpoint.

Definitive Chemoradiation + Immunotherapy (Unresectable)

The PACIFIC regimen — concurrent carboplatin/paclitaxel (or cisplatin/etoposide) + thoracic radiation, followed by durvalumab maintenance for up to 2 years — is standard for unresectable Stage III NSCLC. Trials are testing whether replacing durvalumab with newer agents, or adding a second immunotherapy (CTLA-4 inhibitor), improves on the ~16-month median PFS durvalumab achieves.

Adjuvant Therapy (Post-Surgery)

After surgical resection of Stage IIIA NSCLC: osimertinib is FDA-approved adjuvant therapy for EGFR-mutant patients (ADAURA trial, Stage IB–IIIA). For EGFR wild-type patients, atezolizumab and pembrolizumab have adjuvant approvals. Trials are extending adjuvant immunotherapy to higher-risk populations and testing novel combinations to reduce relapse.

EGFR-Mutant Stage III

EGFR-mutant Stage III patients are a special population. Durvalumab showed poor benefit in EGFR-mutant Stage III patients in the PACIFIC trial subgroup analysis. Current guidelines suggest omitting durvalumab for confirmed EGFR-mutant patients after chemoradiation, and instead considering osimertinib consolidation — supported by the LAURA trial (2024). Active trials are specifically designed for EGFR-mutant Stage III NSCLC to define the optimal post-chemoradiation approach.

Why Molecular Testing Matters at Stage III

Many Stage III patients are not offered comprehensive molecular testing because their disease is being treated locally — but this is changing and the stakes are significant:

EGFR Mutation

Changes adjuvant and maintenance strategy

EGFR-mutant patients: durvalumab maintenance is likely not beneficial (poor PACIFIC subgroup outcomes); osimertinib consolidation after chemoradiation is supported by LAURA trial data. Knowing EGFR status before starting post-CRT treatment is essential. Many adjuvant osimertinib trials require confirmed EGFR status.

PD-L1 Expression

Stratification factor in most Stage III trials

PD-L1 TPS was a key stratification factor in PACIFIC and most subsequent Stage III trials. While durvalumab benefited patients across all PD-L1 levels in PACIFIC, high PD-L1 (≥1%) was associated with greater benefit. Most trials require PD-L1 IHC at enrollment. Know your TPS score.

ALK / Other Fusions

Rare but changes adjuvant options

ALK-positive Stage III patients are candidates for adjuvant alectinib (ALINA trial). RET fusions and other drivers may similarly open adjuvant targeted therapy options as trial data matures. Comprehensive NGS at Stage III diagnosis ensures no adjuvant targeted therapy opportunity is missed.

STK11 / KEAP1 Mutations

Predict poor immunotherapy response

STK11 (LKB1) and KEAP1 mutations are associated with resistance to checkpoint inhibitors, including durvalumab. Identifying these mutations at Stage III may flag patients who are unlikely to benefit from the PACIFIC regimen and should prioritize trial enrollment for novel approaches.

Common questions

Stage III Lung Cancer FAQs

Technically unresectable means surgery would not achieve clear margins or would carry unacceptable risk given tumor location or lymph node involvement — not that it's physically impossible. In practice, resectability for Stage III NSCLC is one of the most debated decisions in thoracic oncology, and different surgeons and multidisciplinary teams reach different conclusions for the same patient. If you've been told your Stage III is unresectable and haven't had an evaluation at a high-volume thoracic oncology center, a second opinion is worth considering — particularly for Stage IIIA with N2 disease, where the evidence for surgery vs. definitive chemoradiation is genuinely contested. This matters for trials because resectable and unresectable Stage III patients qualify for entirely different trial categories.

This is an active clinical debate, and the answer has shifted recently. In the PACIFIC trial, the subgroup of EGFR-mutant patients did not appear to benefit from durvalumab — the hazard ratio for PFS was close to 1.0 in this subgroup. The 2024 LAURA trial showed that osimertinib after chemoradiation significantly improved PFS in EGFR-mutant unresectable Stage III NSCLC, establishing a strong alternative. Current NCCN guidelines now list osimertinib consolidation as a preferred option for EGFR-mutant Stage III patients after chemoradiation, and many centers are moving away from durvalumab in this population. If you're EGFR-mutant and Stage III, discussing LAURA trial data with your oncologist and asking about osimertinib consolidation trials is important before defaulting to the PACIFIC regimen.

The PACIFIC regimen is concurrent chemoradiation (typically carboplatin + paclitaxel or cisplatin + etoposide with thoracic radiation to ~60 Gy) followed by durvalumab (Imfinzi) maintenance immunotherapy for up to 2 years. PACIFIC was a Phase III trial that showed durvalumab maintenance roughly doubled progression-free survival vs. placebo in unresectable Stage III NSCLC, making it the standard of care since 2018. Current trials improving on PACIFIC are testing: adding tremelimumab (anti-CTLA-4) to durvalumab maintenance (POSEIDON-like approaches), replacing durvalumab with newer checkpoint inhibitors, combining radiation with novel immunotherapy agents before or during chemoradiation, and testing stereotactic body radiation (SBRT) as a consolidation boost. If you've recently completed chemoradiation and are starting or considering durvalumab, ask your oncologist whether any maintenance immunotherapy trials are available at your center.

It depends on the trial and where you are in treatment. Most trials for unresectable Stage III NSCLC fall into two categories: concurrent trials (which enroll patients before or at the start of chemoradiation) and maintenance/consolidation trials (which enroll patients after completing chemoradiation, typically within 1–42 days of the last radiation dose). If you're currently mid-chemoradiation, concurrent trials are no longer accessible, but maintenance trials may still be open to you — the enrollment window after completing radiation is often narrow (1–6 weeks), so acting quickly matters. If you're still in treatment planning, now is the best time to ask your oncologist about concurrent Stage III trials before the window closes.

(1) Pathology report confirming NSCLC histology (adenocarcinoma, squamous, or NOS) and ideally IHC markers. (2) Staging workup — CT chest/abdomen/pelvis plus PET scan (most Stage III trials require PET for staging confirmation) plus brain MRI to rule out occult brain metastases. (3) Comprehensive NGS results — especially EGFR status, which changes maintenance options, and PD-L1 TPS. (4) Pulmonary function tests (FEV1, DLCO) — most chemoradiation trials require adequate lung function. (5) Radiation treatment plan showing field coverage and total dose (for maintenance trials enrolling post-chemoradiation). (6) ECOG performance status 0–1 documented by your oncologist — ECOG 2 patients are excluded from most Stage III trials.

Ready to find your matching Stage III trials?

Upload your pathology report, NGS results, or staging scans. We'll map your substage and molecular profile to recruiting trials and give you an eligibility breakdown for each one.

Stage III Lung Cancer